Physician profile
David Savage
NPI 1912403882
$13,899.62
in general payments reported to CMS, 2019-2025
40 companies · $6,361 in 2025
The $6,361 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,465 · 2022: $1,183 · 2023: $3,730 · 2024: $1,161 · 2025: $6,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,438 · Honoraria: $3,400 · Consulting Fee: $3,300 · Education: $577 · Travel and Lodging: $536.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,438.05 |
| Honoraria | $3,400.00 |
| Consulting Fee | $3,300.00 |
| Education | $577.14 |
| Travel and Lodging | $536.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $4,061.02 | 2025 | Ogsiveo, Gomekli |
| Immunocore Limited | $2,266.88 | 2025 | Kimmtrak |
| Catalyst Pharmaceuticals, INC. | $1,615.19 | 2023 | Firdapse |
| Genzyme Corporation | $757.16 | 2022-2024 | |
| Amgen INC. | $712.92 | 2021-2023 | Kyprolis |
| Lilly USA, LLC | $582.68 | 2021-2023 | Jaypirca, Verzenio, Retevmo |
| E.R. Squibb & Sons, L.L.C. | $307.72 | 2023-2024 | Opdivo, Opdualag |
| Daiichi Sankyo INC. | $305.18 | 2021-2024 | Enhertu |
| Janssen Biotech, INC. | $296.41 | 2021-2024 | Tecvayli, Talvey, Erleada |
| Incyte Corporation | $264.60 | 2022-2024 | Jakafi |
| Aveo Pharmaceuticals, INC. | $254.99 | 2021-2024 | Fotivda |
| Eisai INC. | $233.50 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $188.26 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $182.70 | 2023-2024 | Keytruda, Welireg, Lynparza |
| Alexion Pharmaceuticals, INC. | $178.46 | 2021-2024 | Ultomiris |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Savage listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.